Innojin (이노진)
KOSDAQ · KRX: 344860
Innojin is a South Korean biopharmaceutical company listed on KOSDAQ that focuses on the development and commercialization of innovative drug therapies, particularly in areas such as oncology and other therapeutic fields. The company engages in research, development, and manufacturing of pharmaceutical products for both domestic and international markets.
Filing timeline
highspotted 17:40 KST
Innojin (KRX: 344860)- Metamorphosis (메타몰퍼시스) acquired 2,400,000 shares representing 16.63% of Innojin (이노진) outstanding equity
- Acquisition method: subscription to newly issued shares in capital raise with third-party allocation
- Stake reported as of 3 August 2026; filing classified as initial disclosure (신규보고)
View original DART filing ↗mediumspotted 17:40 KST
Innojin (KRX: 344860)- Major shareholder (≥10%) reported owning 2,280,000 shares as of filing date 2026-08-03
- Shareholding represents 15.80% of issued capital
- Filing submitted to Korea Financial Supervisory Service (DART) as insider disclosure report (임원ㆍ주요주주특정증권등소유상황보고서)
View original DART filing ↗AI-generated summaries of public DART filings. May contain errors — always verify against the original (linked). Not investment advice.